摘要
近年来,肠杆菌科细菌对碳青霉烯类抗菌药物的耐药率呈逐年上升趋势,给临床感染治疗带来严峻的挑战.此类感染尚无有效的治疗药物,且病死率极高.为此,一方面我们需要积极开展基础和临床研究,研发与探索有效的治疗药物;另一方面,更需要积极采取控制措施,避免耐药菌株的流行与扩散.
In recent years , the increasing prevalence of carbapenem-resistant Enterobacteriaceae （CRE）poses a serious threat to clinical anti-infection therapy.At present, there are no effective drugs for such infections with high fatality rate.Thus, both basic and clinical studies should be conducted to develop effective antibacterial agents on the one hand , and effective measures should be taken actively to control prevalence and spread of CRE on the other hand.
出处
《中华临床感染病杂志》
2017年第6期401-407,共7页
Chinese Journal of Clinical Infectious Diseases
基金
国家自然科学基金（81361138021）
浙江省重点研发计划项目（2015C03G201049）
关键词
肠杆菌科感染
碳青霉烯类耐药
抗药性
感染控制
Enterobacteriaceae infections
Carbapenems resistance
Drug resistance
Infection control
